Search PubMed⌕ Search

Biomedical subjects

J Roth

Publications and source records attributed to J Roth.

At least 847 records · Page 47Linked to original sources
PubMed1972

Insulin receptors in human circulating cells and fibroblasts.

Human lymphocytes obtained from fasted adult subjects and cultured human tumor lymphocytes were investigated for specific insulin receptors. By use of monoiodoinsulin, specific insulin binding sites were demonstrated in peripheral human lymphocytes, cultured human lymphocytes, and in other types of human circulating cells. Insulins and insulin derivatives that varied in their potency to stimulate glucose oxidation in the fat cell and to inhibit binding of [(125)I]insulin to purified plasma membranes, varied in an analogous fashion in their ability to inhibit the binding of labeled insulin to human lymphocytes. Hormones that had no effect on the binding of insulin to fat cells or liver membranes also had no effect on the binding of insulin to lymphocytes. Binding was time and temperature dependent; dissociation of [(125)I]insulin was rapid upon addition of 10 muM insulin. These findings afford a direct approach to the study of endocrine disorders in man.

Adult↗
PubMed1971

Insulin receptors in the liver: specific binding of ( 125 I)insulin to the plasma membrane and its relation to insulin bioactivity.

With [(125)I]insulin at 7 x 10(-10) M, 25% of the radioactivity was bound to plasma membranes purified from rat liver. 20% of the [(125)I]insulin binding was inhibited by unlabeled insulin at 10(-9) M (6 ng/ml), equivalent to insulin concentrations in hepatic portal blood; inhibition of [(125)I]insulin binding was 80% at 10(-7) M and 90% at 10(-5) M. Eight insulins and derivatives with biological potencies that differed over a 100-fold range inhibited the binding of [(125)I]insulin to liver membranes in direct proportion to their ability to stimulate glucose oxidation in isolated fat cells. Inactive insulin chains, as well as glucagon, ACTH, and human growth harmone were without effect. The binding of [(125)I]insulin increased 55-fold as plasma membrane was purified from crude homogenate. Binding was time- and temperature-dependent, and addition of excess insulin produced rapid dissociation of [(125)I]insulin. This study demonstrates directly the binding of insulin to its biologically important receptors.

Adipose Tissue↗
PubMed1971

Circulating insulin: th proinsulin-like properties of "big" insulin in patients withou islet cell tumors.

When plasma is filtered on Sephadex G-50, insulin immunoreactivity is recovered in two peaks. "Big" insulin, the higher molecular weight component, and "little" insulin, the lower molecular weight component, have elution volumes that correspond to those of proinsulin-(125)I and insulin-(125)I respectively. When plasma was extracted with acid ethanol and filtered in 1.0 M acetic acid, the patterns and proportions of "big" and "little" insulin were indistinguishable from those obtained by filtration of whole plasma in neutral buffer. When "big" insulin was isolated from plasma and mixed with a tracer of porcine proinsulin-(125)I, trypsin converted the "big" insulin immunoreactivity to the gel filtration pattern of "little" insulin in the same way that it converted the proinsulin radioactivity. More than 90% of both "big" insulin and proinsulin were converted at optimal trypsin concentrations. Our present guinea pig anti-insulin serum failed to distinguish "big" from "little" but a porcine proinsulin anti-serum, under appropriate conditions of assay, reacted strongly with "big" insulin but not at all with "little." When tested on isolated fat cells, "little" insulin had the same bioactivity as porcine insulin, whereas "big" insulin had the same low activity as porcine proinsulin. These studies suggest that "big" insulin represents either single-chain proinsulin and/or a proinsulin intermediate that has similar low bioactivity.

Adenoma, Islet Cell↗
PubMed1971

Proinsulin-like component of circulating insulin in the basal state and in patients and hamsters with islet cell tumors.

The proinsulin-like component comprised approximately 20% of total circulating basal immunoreactive insulin in 15 patients without islet cell tumors. 15 min after oral glucose, the concentration of the proinsulin-like component was unchanged and its percentage of the total immunoreactive insulin decreased with the acute release of the insulin component. By 2 hr after oral glucose, the concentration of the proinsulin-like component increased and the insulin component concentration decreased so that the percentage of the proinsulin-like component was essentially the same as in the basal state. In five patients with islet cell tumors and fasting hypoglycemia, basal proinsulin-like component ranged from 26 to 79% of the total immunoreactive insulin. While basal proinsulin-like component was higher in the islet cell tumor patients, the fluctuations after stimulation were qualitatively similar to the nontumor patients. Acute stimulation with glucose, tolbutamide, leucine, and streptozotocin mainly released the insulin component resulting in a fall in the per cent proinsulin-like component with a subsequent increase in percentage of this component as the total insulin concentration returns towards basal levels. Three islet-cell tumor patients with less than 46% proinsulin-like component had favorable therapeutic responses to diazoxide whereas one patient with over 80% proinsulin-like component was completely refractory. Syrian hamsters bearing islet cell tumors provided an excellent model for islet cell tumors in man. These animals have a high proportion of a proinsulin-like component in plasma; stimulation of tumor slices in vitro with tolbutamide and glucagon releases mainly the insulin component similar to the observations in man. These studies suggest that the mechanisms regulating the release of the proinsulin-like and of the insulin components are different.

Acromegaly↗